Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/11059
Title: Implants composed of digoxin and poly(ε-caprolactone) : development, characterization, anti-proliferative and anti-angiogenic activities.
Authors: Rodrigues, Felipe Fernandes
Braz, Wilson Rodrigues
Perasoli, Fernanda Barçante
Ferreira, Letícia Gonçalves Resende
Barbosa, Leandro Augusto de Oliveira
Silva, Gisele Rodrigues da
Issue Date: 2017
Citation: RODRIGUES, F. F. et al. Implants composed of digoxin and poly(ε-caprolactone) : development, characterization, anti-proliferative and anti-angiogenic activities. Pharmazie, v. 72, n. 7, p. 383–388, 2017. Disponível em: <https://www.ingentaconnect.com/contentone/govi/pharmaz/2017/00000072/00000007/art00002>. Acesso em: 25 fev. 2019.
Abstract: Drug delivery systems could be applied to locally treat cervical cancer, thus preventing the drawbacks of conventional therapy. In this study, anti-proliferative and anti-angiogenic effects of digoxin incorporated into poly(ε-caprolactone) implants were evaluated, aiming at the local treatment of cervical cancer. Implants were characterized, and the in vitro release profile of digoxin was demonstrated. Anti-proliferative and anti-angiogenic activities of digoxin were investigated by using chorioallantoic membrane and human cervix carcinoma (HeLa) cells, respectively. The chemical structure of digoxin and the semi-crystalline nature of poly(ε-caprolactone) were preserved after designing implants. The hydrophobicity of drug and polymer as well as the semi-crystalline structure provided a controlled diffusion of digoxin from implants. Digoxin released from implantable devices exhibited anti-proliferative activity against HeLa cells. The anti-angiogenic effect was also shown. Finally, implants composed of digoxin and poly(ε-caprolactone) could be applied as a therapeutic alternative to treat the early stage of cervical cancer, once they were able to locally control the release of this anti-angiogenic and anti-proliferative drug, minimizing its systemic side effects and toxicity.
URI: http://www.repositorio.ufop.br/handle/123456789/11059
metadata.dc.identifier.uri2: https://www.ingentaconnect.com/contentone/govi/pharmaz/2017/00000072/00000007/art00002
ISSN: 0031-7144
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_ImplantsComposedDigoxin.pdf365,55 kBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.